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Introduction 
    In recent decades, diabetes has been more prevalent 
worldwide. The principles of adequate therapy for 
diabetes include nutritional therapy, exercise, and 
pharmacological treatment [1]. Several guidelines for 
diabetes have been proposed so far [2]. In 2021, 
American Diabetes Association (ADA) presented a new 
standard method for adequate diagnosis and treatment 
for diabetes [3]. The therapeutic perspectives         
have  to   be  considered  from  macroangiopathic   and  
microangiopathic points of view [4].  
 
    As regards to diabetic therapy, nutritional therapy is 
a fundamental principle. Formerly, the standard 
method was Calorie Restriction (CR), which means 
decreasing intake of fatty food. After that, a variety of 
health care and medical care have brought the changes 
into a Low Carbohydrate Diet (LCD). LCD means the 
restriction of the amount of carbohydrate, irrespective 
of taking fatty or high-calorie foods. LCD was begun by  
Abstract 
    The patient was a 74-year-old female with type 2 diabetes mellitus (T2DM) treated on Humalog mix 25 
twice a day. As social history, she has worked long years for growing and harvesting lotus roots. It gives 
physically heavy loading, which brings unstable glycemic daily control. She had to titrate minute regulation 
every time. For stable glucose variability, the treatment was changed to Xultophy, which is a  specific 
combined agent of Insulin Degludec and Liraglutide (IDeg/Lira) once a day. Then, detailed glucose monitoring 
showed a better daily profile of blood glucose, irrespective of heavy or light work. It showed the bio-psycho-
social benefit of Xultophy. 
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Dr. Atkins et al., in European and western countries 
[5]. The clinical effect of LCD has been prevalent for 
long with several pieces of evidence [6,7]. In contrast, 
the authors and co-researchers in Japan have initiated 
LCD and developed LCD movements so far [8]. In 
order to make LCD understood in broad fields, we have 
established a newly Japan LCD Promotion Association 
(JLCDPA). Successively, we tried to make various 
chances to develop LCD socially, medically, and 
educationally using books, seminars, and workshops 
[9]. When people can apply LCD in their daily lives, 
three kinds of LCD are recommended. They are petite-
LCD, standard-LCD, and super-LCD, which contain 
carbohydrate in calorie ratio as 40%, 26%, and 12%, 
respectively [10]. In addition, a variety of researches 
have been continued including continuous glucose 
monitoring (CGM), meal tolerance test (MTT), 
insulinogenic index (IGI), a daily profile of blood 
variability, Morbus (M) value, and actual use and 
combined agents of Xultophy [11]. 
 
    From a pharmacological point of view, various types 
of hypoglycemic agents were applied for long. Some 
are oral hypoglycemic agents (OHAs) and others are 
injectable agents [12]. The latter includes some kinds 
of glucagon like peptide-1 receptor agonists (GLP-
1Ras), such as liraglutide, exenatide, dulaglutide, 
lixisenatide, and so on [13]. Related to several research 
for GLP-1RAs, clinically useful evaluation has 
summarized by the Network Meta-Analysis (NMA) for 
better glycemic control as well as research outcomes of 
cardiovascular disease (CVD) [14]. Consequently, 
beneficial cardiometabolic efficacy has been observed  
for applying GLP-1Ras.  
 
    Among several GLP-1Ras, liraglutide has been 
known and used broadly for patients with type 2 
diabetes mellitus (T2DM). After lots of practice and 
research, Xultophy was produced as the combined 
agents of insulin degludec and liraglutide (IDeg/Lira) 
[15]. Insulin degludec has a role of basal insulin, which 
provides the decreased fasting blood glucose. GLP-1Ra 
gives the decreased levels of pre-prandial and post-
prandial glucose [16]. The combination of these agents 
with an ideal fixed ratio would make improved glucose 
variability by providing only one injection a day. In 
fact, Xultophy showed various  studies  with  improved 
 
efficacy of glucose control in comparison with the 
result of one agent [17]. Furthermore, it has a 
beneficial effect of cardioprotective mechanism by 
elevating the endocrinological function of β-cell of the 
pancreas [18]. 
 
    The authors and co-researchers have continued 
practice and several reports concerning diabetes and 
related treatments. Among these clinical experiences, 
an older female patient with T2DM showed impressive 
progress. She received formerly insulin therapy twice a 
day, and her glycemic control was rather unstable. 
When the treatment was changed to Xultophy with one 
injection, her lifestyle became satisfactory with less 
psychological and social stresses. Her clinical course 
and some perspective from bio-psycho-social points of 




    The patient was pointed out to have T2DM and 
hypothyroidism about 20 years ago. For her treatment, 
she was initially given OHAs and levothyroxine 50 μg 
1T per day. Successively, insulin treatment was 
initiated about 10 years ago. She was treated for 
hemorrhoid 8 years ago. On Nov 2018, laboratory data 
showed that Hb 11.6 g/dL and MCV value dropped 
from 87.3 to 81.8, suggesting the possibility of anemia 
and bleeding of gastro-intestinal and colon. The 
endoscopic examination for upper and lower GI tracts 
showed no significant changes for bleeding foci. 
 
    From 2019 to 2021, she has been treated on 
Humalog Mix 25 twice daily as an insulin treatment for 
her diabetes. She has been working hard every day as a 
farmer, growing and harvesting lotus roots. She has 
continued self-monitoring blood glucose three times a 
day and constantly adjusted her insulin dose. From Dec 
2020, she felt some difficulty in proper glycemic 
control, and then the treatment was changed from 
insulin to once-daily Xultophy. 
 
Current Physicals & Exams: 
    Consciousness is alert, and speech is normal without 
abnormality. Vitals are normal including pulse BP, 
respiration, and SpO2 level. Physicals are within
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normal limits such as body mass index (BMI), lung 
heart, and abdomen. Neurological findings are 
negative for diabetic neuropathy. 
 
    Several fundamental laboratory data are as follows: 
Hb 11.2 g/dL、RBC 359 x 10
6 
/μL、Ht 35.9%、MCV 87.3 
fL（80-98）、MCH 27.3pg（27-34）、MCHC 31.2 g/dL
（31-36）、WBC 4200 /μL 、Plt 20.9 x 10
4
 /μL、BUN 18 
mg/dL、Cr 0.7 mg/dL, uric acid 2.2 mg/dL、eGFR 70.2 
mL/min/1.73m2、TG 61 mg /dL、HDL-C 83 mg/dL、 
LDL-C 76 mg/dL、TC 180 mg/dL、TP 7.1 g/dL、AST 26 
U/L、ALT 10 U/L、γ-GT 25 U/L、ALP 359 U/L (203-
460)、LDH 324 U/L（100-340）、T-Bil 0.6 mg/dL、
amylase 128 U/L（35-125）、CRP 0.04 mg/dL、HbA1c 
8.0%、fasting blood glucose 189 mg/dL、 
 
    Other exams are included in the following:  
1. Chest X-ray and ECG showed unremarkable 
2. Ophthalmic test was negative for retinopathy 
3. Vascular extensibility test showed Ankle-
brachial index (ABI) 1.12/1.12. cardio-ankle 
vascular index (CAVI) 8.8/8.6.  
 
Result 
    The changes in major laboratory findings over the 
last few years are shown in Table-1. HbA1c level has 
been recently on a slight upward trend. The value of 
hemoglobin (Hb) did not change, and the MCV value 
dropped to 81 once in Nov 2018, but otherwise, MCV 
was stable. In addition, there were no changes in liver 
function, lipids, CRP, and others. 
 
Table-1: Changes in fundamental biomarkers  
  
2017 2018 2019 2020 2021 
July Nov May Nov June Feb Sept Feb 
HbA1c (%) 7.7 7.5 7.8 7.4 7.8 7.9 8.0  8.0  
glucose (mg/dL) 148 105 148 202 182 244 145 252 
Hb (g/dL) 9.7 12.1 11.4 11.6 11.3 11.5 11.4 11.2 
MCV (fL) 89.3 87.8 87.3 81.8 93 91.8 84.8 87.3 
WBC (/mcL) 4500 4400 4000 3600 3000 4500 3700 4200 
AST (IU/L) 23 22 19 21 29 26 25 26 
LDL (IU/L) 126 130 111 121 129 126 119 126 
CRP (mg/dL) 0.05 - 0.04 - 0.02 - 0.04 - 
 
    From Feb 2021, the treatment for diabetes was 
changed. Formerly, Humalog mix 25 was administered 
twice a day, but it was changed to Xultophy once-daily 
injection. Table-2 shows the details of the changes in 
the daily profile of blood glucose. Among them, on 
Days -1 to -5, self-blood glucose measurement was 
performed three times a day, and the units of Humalog 
mix 25 was adjusted. For days 1 to 3, we started with 
Xultophy from 6, 8, 10 doses. Since blood glucose 
dropped to 59 mg/dL in the evening of day 5, the unit 
was set to 9 doses from the next day. On days 11-16, 
blood glucose was measured 3 times a day on both  
pre-prandial and 60 min post-prandial time.                
Blood glucose 60 minutes after breakfast was over                          
200 mg/dL in 4/5. On the other hand, 60 minutes  
after lunch and 60 minutes after dinner, a total of 12 
times (12/12) were within the range of 123-175 mg / 
dL. After day 17, her Xultophy doses were stable at 7-8 
doses. 
 
Problems and Prescriptions 
    From the above, the current medical problems can 
be summarized as follows: 
1. T2DM: The medical history has 20 years, and no 
particularly remarkable microangiopathy or 
macroangiopathy is observed. 
2. Treatment of T2DM: Insulin on Humalog  mix 25  
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twice was changed to Xultophy once a day. 
3. Hypothyroidism: Medical history has 20 years, 
which is stable with the administration of 
levothyroxine. 
4. GERD: Grade D (reflux esophagitis). 
5. Social status: Her occupation has been a farmer, 
which has been hard work outside. Consequently, 
she has checked blood glucose three times a     





    For the related problems mentioned above, the 
prescription was as follows: i) Metformin 
(Metogluco®) 500mg, ii) levothyroxine (Thyradin S®) 
50 mcg 1T, iii) Lansoprazole (Takepron®) 15mg 1T, iv) 
linagliptin (Trazenta®) 5mg 1T. After starting 
Xultophy, prescription i) to iii) were continued, and iv) 
was discontinued. 
     Table-2: Changes in Blood Glucose 
Day Blood Glucose Mix 25 
Xultophy Dose 
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Discussion 
    From a historical point of view, diabetic treatment 
was developed using several OHAs and a few types of 
injections including insulin and GLP-1Ra. In order to 
get a better glucose profile, insulin therapy was 
proposed as a basal-bolus regimen [12]. Consequently, 
multiple daily injection (MDI) has been recognized    
for recommended strategy. Indeed, it is rather        
ideal to continue MDI, but multiple injections     
require much loading to a patient and also family. 
Recently, Xultophy was introduced to clinical practice, 
which is a convenient and effective way of treatment 
[15]. 
 
    As regards to Xultophy, consecutive investigation of 
clinical efficacy was found. It has been the 
European Xultophy Treatment Retrospective Audit, 
which is usually called as EXTRA. The related 
investigation would be a real-word evidence (RWE) 
study (EXTRA) where data are from many diabetes 
centers in European countries [19]. The result revealed 
that HbA1c was significantly decreased by 0.7%, and 
weight was decreased by 2.4kg, when treatment was 
changed from MDI to Xultophy for half year. The 
subjects of EXTRA study included 5 countries with > 
600 patients. As a result, the initiation therapy caused 
HbA1c value -0.9% significantly for half year [20]. 
From mentioned above, Xultophy is evaluated to have 
not only remarkable efficacy but also beneficial and 
useful regular lifestyle for diabetic patient and also the 
family. 
 
    In this current case, diabetic treatment was changed 
from Humalog mix 25 twice a day to Xultophy once a 
day. The initial amount was 6 doses. According to the 
standard regimen of Xultophy, the start dose would be 
16 doses in the case of previously treated on insulin, 
and 10 doses for naive case of insulin [16]. However, 
different circumstances may exist among European, 
North American, Eastern or Asian countries. Authors 
reported a diabetic case treated by Xultophy with 
smaller doses than usual [21]. Current case has 
changed the Xultophy doses from 6 to 10, and after 
that 7 or 8 finally, which were smaller doses. This 
characteristic point may be the synergy effect of 
combined agents of Xultophy [16]. Other reasons    
may  be  from the  specific background of  the patients.  
 
They  are i) older  age, ii) long  diabetic period, and iii)   
physically hard working every day.   
 
    In this current investigation, detailed feedback and 
impression were obtained from the patient herself. 
Several perspectives regarding the response and 
efficacy of Xultophy are found. They are i) post-
prandial blood glucose did not rise so much as 
expected compared to before, ii) when eating snacks at 
night, glucose in next morning was not so higher than 
expected, iii) pre-prandial glucoses on noon and 
evening after hard working is not so low as expected, 
iv) For hypoglycemic period, the falling speed of 
glucose is slower than before, v) In the case of 
hypoglycemia with the same glucose level, the 
symptoms that the body feels are milder than before. 
From mentioned above, Xultophy seems to have 
clinically beneficial effects in the light of diabetic 
patient oneself. 
 
    Current case can be evaluated in the light of bio-
psycho-social aspects [22]. The first aspect is bio-
perspective. In comparison with Humalog mix 25, 
Xultophy can bring better glucose variability with only 
one injection. The second is psycho-perspective [23]. 
The case feels easy because of a less anxious episode 
for hypoglycemia. The third is social-perspective. 
Formerly, the case was limited to stay in a small area 
from home to working farm, because she was anxious 
for glucose control. With Xultophy, she can depart 
some distance for social activity. Her HbA1c for Feb, 
Mar, April 2021 was stable, which indicated the benefit 
of Xultophy.  
 
    In this article, some limitations are present. Only 
one case was reported with beneficial results of 
application for Xultophy. Future accumulation of 
adequate cases with Xultophy will be necessary. In 
actual diabetic practice, we always consider several 
aspects of the background of the patient [24]. 
 
    In summary, a female T2DM patient showed 
satisfactory progress with Xultophy, associated with 
some discussion. This report includes an impressive 
perspective and will hopefully become a reference for 
future practice and research. 
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